A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,414actual
Sites
61
Countries
China, South Korea, Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-29 | actual | When the study began enrolling |
| Primary completion | 2025-05-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-30 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-14 | actual | When this record first appeared on the registry |
| Results posted | 2026-05-22 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Interventions
- Drug: Zavegepant
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants With Pain Freedom at 2 Hours Post-dose
measured At 2 hours post-dose
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
measured At 2 hours post-dose
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-02-22 · 719 KB · Prot_000.pdf
Statistical Analysis Planposted 2025-05-28 · 889 KB · SAP_001.pdf
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed